Human papillomavirus, or HPV, is not one virus but a family of more than a hundred related strains. Around forty of them infect the genital tract, and about fourteen of those are classified as high-risk because they can drive cancer if the infection lingers for years.

HPV is the most common sexually transmitted infection on Earth. Most sexually active adults will encounter it at some point. The good news is that in the vast majority of cases the body clears the virus quietly within a year or two, with no symptoms and no lasting harm.

The trouble starts in the small fraction of people whose immune system cannot clear a high-risk strain. Over five to twenty years, persistent infection can slowly change cervical cells, then pre-cancer cells, and eventually invasive cancer. Two strains alone — HPV 16 and HPV 18 — are responsible for roughly seventy percent of cervical cancers worldwide and in India.

HPV is not only a cervical cancer story. It also causes most cancers of the anus, a large share of throat and tongue cancers, and many vulvar, vaginal, and penile cancers. This is why the vaccine matters for boys too, not just girls.

Cervical cancer is the second most common cancer in Indian women, with around one and a quarter lakh new cases and seventy-five thousand deaths every year. That accounts for nearly a quarter of the global cervical cancer burden, even though India holds about a sixth of the world's women.

The cancer is slow. From first HPV exposure, it usually takes a decade or more for invasive cancer to develop. That long window is exactly what makes prevention so effective: vaccination before exposure stops most infections; screening after exposure catches the rest before they become dangerous.

The World Health Organization has set a global elimination goal: by 2030, 90 percent of girls vaccinated by age 15, 70 percent of women screened by ages 35 and 45, and 90 percent of those needing treatment receiving it. India is a long way from that 90 percent vaccination target — current coverage is in the low single digits — which is why every family conversation about the vaccine moves the needle.

For broader literacy on understanding scan and lab reports your gynaecologist may order during screening, see Understanding Scans, Labs & Reports: A Complete India Pregnancy Guide.

An HPV vaccine does not contain the live virus. It contains protein shells — called virus-like particles — that look identical to the outside of HPV to the immune system but carry no genetic material and cannot cause infection or cancer. Your immune system practises on these decoys and builds antibodies that recognise the real virus instantly if it shows up later.

Real-world data from countries that vaccinated early is now striking. In Scotland, cervical cancer cases in women vaccinated at 12 or 13 have dropped to effectively zero in long-term follow-up. Australia, which started its programme in 2007, is on track to functionally eliminate cervical cancer within the next decade. India can travel that same road, but only if vaccination becomes a normal teenage milestone, not a whispered private decision.

The vaccine works best before exposure to HPV, which is why the recommended age window starts at 9. It still offers significant protection at older ages, just less of it, because some HPV strains may already have been encountered.

Importantly, the vaccine does not treat existing HPV infections, existing genital warts, or existing pre-cancer. Screening is the tool for catching what has already started; vaccination is the tool for preventing what has not.

• Cervavac is India's first indigenous HPV vaccine, developed by the Serum Institute of India and launched in September 2022. It is quadrivalent, meaning it protects against four HPV strains — 6, 11, 16, and 18. Types 16 and 18 are the major cervical-cancer drivers; types 6 and 11 cause around 90 percent of genital warts.
• Gardasil 9, made by Merck and imported into India, is nonavalent — it protects against nine HPV strains: 6, 11, 16, 18, 31, 33, 45, 52, and 58. Adding those five extra high-risk strains pushes its cervical-cancer prevention coverage from around 70 percent to around 90 percent.
• Both vaccines are highly effective, both are approved by India's drug regulator (CDSCO), and both have strong global and Indian safety data. Cervavac was specifically priced and engineered for the Indian context; Gardasil 9 offers wider strain coverage at a higher price.
• Cost in India: Cervavac is roughly 2,000 rupees per dose at private clinics. Gardasil 9 typically runs 3,500 to 4,500 rupees per dose. Multi-dose totals matter — a three-dose Gardasil schedule for an adult can cost over 12,000 rupees, while Cervavac comes in at around 6,000 rupees.
• The older bivalent Cervarix and quadrivalent Gardasil 4 are largely being phased out of Indian private practice in favour of Cervavac and Gardasil 9; if a clinic still stocks them, ask about availability of the newer options.
• Bottom line: any HPV vaccine is dramatically better than none. If cost is a barrier, Cervavac at 2,000 rupees per dose is an excellent choice. If budget allows, Gardasil 9's broader coverage is worth considering, especially for older catch-up vaccination.

• Primary target: girls aged 9 to 14. This is the sweet spot, before most sexual debut, when the immune response to the vaccine is also strongest. Two doses are enough in this age band.
• Catch-up: girls and women aged 15 to 26 should still be vaccinated as soon as possible. From age 15 onwards, a three-dose schedule is needed.
• Extended catch-up: Indian and international bodies now support vaccination up to age 26, and many gynaecologists offer it up to age 45 after a shared-decision conversation about likely benefit. Even after sexual debut, the vaccine still protects against strains you have not yet encountered.
• Boys and men: HPV vaccination is approved and recommended for boys aged 9 to 14, and through the same catch-up windows. It prevents anal, penile, throat, and tongue cancers in men, and dramatically reduces household and partner transmission.
• People living with HIV, organ transplant recipients, and others with weakened immune systems: vaccinate on a three-dose schedule regardless of age, and discuss timing with your specialist.
• Always before sexual debut if possible; still strongly worthwhile after it.
• Pregnancy: postpone the vaccine series till after delivery. The vaccine does not affect future fertility and is safe while breastfeeding, but starting or finishing the series during pregnancy is not recommended only because data is still limited. If you started the series and then conceived, the remaining doses are simply delayed until postpartum.

For ages 9 to 14: a two-dose schedule. The second dose is given 6 to 12 months after the first. Younger immune systems mount such a strong response that two doses provide protection equivalent to three doses given later.

For ages 15 and above (including catch-up): a three-dose schedule. The standard timing is month 0, month 2, and month 6. Cervavac and Gardasil 9 both follow this schedule for older recipients.

If a dose is delayed, you do not need to restart the series. Pick up where you left off; the immune system remembers. Still, try to complete the series within 12 months for the strongest response.

For Cervavac, the manufacturer recommends 0–2–6 months for 15+ and 0–6 months for 9–14. Gardasil 9's older 0–2–6 schedule has been streamlined to 0–6 months for 9–14-year-olds based on updated immunogenicity data.

Vaccination is given as an intramuscular injection, usually in the deltoid (upper arm) muscle. The needle is small; the whole shot takes a few seconds.

WHO is now reviewing single-dose evidence for the 9-to-14 age band; some countries have already moved to a single dose. India has not yet adopted single-dose protocols, so plan on two for younger girls and three for everyone else.

• Cervavac (SII): around 2,000 rupees per dose at most private clinics and hospital chains. Total course: roughly 4,000 rupees for ages 9 to 14 (two doses), 6,000 rupees for ages 15 and above (three doses).
• Gardasil 9 (Merck): roughly 3,500 to 4,500 rupees per dose privately. Total course: around 8,000 rupees for ages 9 to 14, 12,000 to 14,000 rupees for ages 15 and above.
• Government provision: the Union Budget of February 2024 announced national rollout of HPV vaccination for girls aged 9 to 14, with gradual scale-up under the Universal Immunization Programme. Sikkim was the first state to run a free school-based programme starting in 2018; other states have piloted similar models. Free access is still patchy, so check with your district's health office for current camps and eligibility.
• Private hospital chains like Apollo, Fortis, Manipal, Cloudnine, Rainbow, and Motherhood usually keep both vaccines in stock. Paediatricians are ideal for the 9 to 14 age band; gynaecologists for 15 and above.
• Many family physicians and general clinics now stock Cervavac; ask the pharmacy or call ahead so they can order it if it is not on the shelf.
• Most Indian health insurance does not yet cover HPV vaccination as it is classified preventive. A few corporate group plans and select retail plans now include it; check your policy before assuming it is covered.
• Storage: HPV vaccines need a strict cold chain. Buy from licensed pharmacies, vaccination centres, or directly through a clinic — not from unverified online sellers.

• Most common: soreness, redness, or mild swelling at the injection site for one to two days. A cool compress and your usual paracetamol help.
• Common: a mild fever, fatigue, headache, or muscle ache for a day or two after the dose. Rest and fluids.
• Less common: nausea, dizziness, or a brief fainting episode immediately after the shot — more often seen in teenagers and not vaccine-specific. Most clinics will ask you to sit for 15 minutes after the dose for this reason.
• Rare: an allergic reaction, usually within minutes of the shot, which is exactly why the post-vaccination wait exists. Severe allergic reactions are treatable on the spot.
• Not linked to: infertility, premature menopause, autoimmune disease, or chronic fatigue syndrome. Large, long-term studies in millions of recipients have repeatedly debunked these claims.
• Call your clinic if a fever above 38.5°C lasts more than 48 hours, swelling spreads rapidly, you develop a rash with breathing difficulty, or anything feels seriously wrong. Most side effects resolve in two days without intervention.

• Myth: the HPV vaccine encourages early sexual activity. Fact: every major study has found no link between vaccination and earlier sex, more partners, or risky behaviour. The vaccine works best before exposure; that is biology, not permission.
• Myth: only sexually active people need it. Fact: the vaccine is most effective before sexual debut. Vaccinating at 9 to 14 is the strongest possible move; waiting until adulthood loses some of the benefit.
• Myth: married, monogamous women do not need it. Fact: HPV can transmit from a single past partner, can have been carried silently for years, and a current monogamous partner can have been previously exposed. Vaccination still adds meaningful protection for many married women under 45.
• Myth: my daughter is too young to discuss this. Fact: paediatricians give the shot during a routine appointment with a brief age-appropriate explanation — usually no more than that it protects against a serious cancer years later. No graphic conversation is required.
• Myth: the vaccine is unsafe or experimental. Fact: HPV vaccines have been studied in tens of millions of recipients over almost two decades. Safety profile is excellent and on par with other routine childhood vaccines.
• Myth: if I have the vaccine, I do not need Pap smears. Fact: the vaccine does not cover every cancer-causing strain and does not treat infections you already have. Screening from age 30 is still essential for life.
• Cultural shame and silence remain the biggest non-medical barrier; naming it openly with family and friends is part of the work. See Cultural Shame vs. Body Awareness: Reclaiming Your Narrative.

The vaccine prevents the strains it targets, but no vaccine in any field is 100 percent. Around 10 to 30 percent of cervical cancers are caused by HPV strains outside the current vaccine coverage. Screening catches those.

From age 30, Indian and international guidelines recommend a Pap smear every three years, or a Pap-plus-HPV co-test every five years — even if you have been fully vaccinated. Screening is not optional just because the vaccine was completed in adolescence.

Body awareness still matters for early detection. Knowing your normal cycle, noticing unusual bleeding between periods or after sex, recognising new pelvic pain or discharge — these are the symptoms that should prompt a gynaecology visit at any age. See breast-self-exam-india for a parallel self-awareness practice in breast health.

Boosters: current evidence suggests immunity from the HPV vaccine is long-lasting — at least 12 to 15 years and likely lifelong. No booster doses are recommended at this time.

Travel and migration do not reset the schedule. If you start the series in India and move abroad mid-course, finish with any approved HPV vaccine; the schedule is interchangeable.

• Cervavac's launch in September 2022 was a turning point. Before Cervavac, the only options were Gardasil 4 and Cervarix at imported prices that put the vaccine out of reach for most Indian families. Cervavac slashed the per-dose cost by more than half.
• The 2023 Union Budget formally announced national HPV rollout, with the 2024 Budget reaffirming gradual integration into the Universal Immunization Programme. Implementation is rolling out state by state; ask your district health office for the current status.
• School-based delivery is the most efficient model worldwide. Sikkim's school programme achieved over 95 percent coverage; states like Punjab, Telangana, and parts of Maharashtra have run similar pilots. Parental consent is required.
• Stigma around the word "sexually transmitted" still derails conversations. Reframing HPV as a cancer-prevention vaccine — which is what it actually is — opens far more doors with hesitant grandparents and extended families.
• Cost-sharing within families: many Indian families now bundle the HPV vaccine into a daughter's school health check-up or annual paediatric visit. Spreading three doses over six months also spreads the cost.
• Sons are still being skipped. Indian uptake among boys is even lower than among girls. Vaccinating boys protects them from anal and oropharyngeal cancers and protects their future partners. Ask explicitly for it at your paediatrician.
• Government camps remain rare for the moment, but private OPDs, paediatric clinics, and gynaecologists are widely available in cities and tier-two towns. Tier-three towns and rural areas still face significant access gaps.

The HPV vaccine is one of the most studied, safest, and most effective vaccines ever developed. In a country where cervical cancer kills more women than any other gynaecological cancer, every dose delivered is a life statistically saved decades down the line.

If there is a girl in your family between 9 and 14, this is the single most important medical decision of her preteen years. Two doses, 2,000 rupees each, six months apart. That is it.

If there is a young woman between 15 and 26, do not wait. Three doses, still highly effective, still life-changing.

If there is an adult woman under 45 who has not yet been vaccinated, have the conversation with your gynaecologist. The marginal benefit at older ages is smaller, but for many it is still meaningful.

If there is a boy in your family, do not skip him. Vaccinate sons alongside daughters; it is the same shot, the same schedule, the same protection — just less talked about.

And then, when the time comes, follow it up with regular screening from age 30. Vaccination plus screening is the combination that ends cervical cancer. India can be one of the countries that gets there.